Graphene Photothermal Adjuvant Therapy for Mild Corona Virus Disease 2019: A Prospective Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Following enrollment, patients will be randomized into treatment or control groups. All groups will receive the same conventional therapy.
In addition, treatment groups will undergo Graphene adjuvant therapy 30 minutes per day for 7 d.
Upon completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Songqiao Liu, PhD.
- Phone Number: 086-02583262550
- Email: liusongqiao@ymail.com
Study Contact Backup
- Name: Junjing Zhang
- Phone Number: 086-04175281618
- Email: zhang.jj@vip.163.com
Study Locations
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, China, 010031
- Recruiting
- Hohhot First Hospital
-
Contact:
- Junjing Zhang
- Phone Number: 086-04175281618
- Email: zhang.jj@vip.163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet the diagnostic criteria for mild COVID-19.
- Patients aged 18-60 years (inclusive).
- No later than 48 h after testing positive and the onset of clinical symptoms
- Sign informed consent form.
Exclusion Criteria:
- Severe or critically patients with COVID-19.
- Resting heart rate over 120 beats per minute.
- Coronary heart disease patients with acute cardiac insufficiency.
- Acute exacerbation of chronic obstructive pulmonary disease(COPD).
- Uncontrolled hypertension [resting systolic blood pressure(SBP) more than 180 mmHg and diastolic blood pressure(DBP) more than 90 mmHg]; uncontrolled diabetes(Random Plasma Glucose, RPG>16.7mmol/L, HbA1C>7.0%)
- Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases.
- Pregnant or menstruating woman.
- Known or suspected history of active tuberculosis or extrapulmonary tuberculosis, patients with brucellosis, pneumonia-related illness from other causes
- COVID-19 patients for the second or more times
- Those who cannot cooperate due to various reasons
- Body temperature: more than 38℃.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Graphene adjuvant therapy combined with conventional therapy group (treatment group)
Graphene adjuvant therapy combined with conventional therapy group (treatment group):Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.
|
Undergo 30-min of graphene adjuvant therapy every day for 7 d.
|
|
No Intervention: Conventional therapy group (control group)
Conventional therapy group (control group):Patients will only receive the conventional treatment for COVID-19.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The time from positive at baseline to negative SARS-CoV-2 nucleic acid test
Time Frame: through study completion, an average of 10 days
|
The time for grouped patients to receive a negative SARS-CoV-2 nucleic acid test result, including both ORF gene Ct value≥35 and N gene Ct value≥35.
|
through study completion, an average of 10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospital stay
Time Frame: through study completion, an average of 15 days
|
Time to hospitalization for COVID-19
|
through study completion, an average of 15 days
|
|
Negative test rate within 7 days
Time Frame: 7 days
|
the rate of negative test of patients
|
7 days
|
|
Mild to moderate rate within 14 days
Time Frame: 14 days
|
Mild to moderate rate within 14 days
|
14 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lymphocytes variation
Time Frame: through study completion, an average of 15 days
|
Lymphocytes count
|
through study completion, an average of 15 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Songqiao Liu, PhD., Southeast university
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB2022075
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.